Company news

Shandong Lukang Pharmaceutical Co., Ltd. Class A (SSE:600789) news

Shandong Lukang Pharmaceutical Co., Ltd. Class A news releases on 6ix. Latest, Sep 30, 2026: (600789)"Shandong Lukang Pharmaceutical Co., Ltd."Announcement…

Shandong Lukang Pharmaceutical Co., Ltd. Class A (SSE:600789) news

Press releases & updates

(600789)"Shandong Lukang Pharmaceutical Co., Ltd."Announcement on Resolutions of the 17th (Extraordinary) Meeting of the 11th Board of Directors

(600789)"Shandong Lukang Pharmaceutical Co., Ltd."Announcement on Obtaining Drug Registration Certificate

(600789)"Shandong Lukang Pharmaceutical Co., Ltd."Announcement on Adjustment to Certain Senior Executives

"Shandong Lukang Pharmaceutical Co., Ltd."Announcement on Change of the Signing Certified Public Accountant

"Shandong Lukang Pharmaceutical Co., Ltd."Announcement on Obtaining Drug Registration Certificate and Approval Notice for Marketing Application of Chemical API

"Shandong Lukang Pharmaceutical Co., Ltd."Announcement on Convening the 2026 Semi-annual Performance Briefing

"Shandong Lukang Pharmaceutical Co., Ltd."Special Report on the Deposit, Management and Actual Use of Raised Funds

"Shandong Lukang Pharmaceutical Co., Ltd."Announcement on the Controlled Subsidiary Obtaining the Supplementary Application Approval Notice for Crisaborole Ointment and Becoming the Marketing Authorization Holder of the Drug

"Shandong Lukang Pharmaceutical Co., Ltd."Announcement on Obtaining Notice of Approval for Marketing of Chemical API for Lenvatinib Mesylate

"Shandong Lukang Pharmaceutical Co., Ltd."Announcement on Obtaining Drug Registration Certificate

"Shandong Lukang Pharmaceutical Co., Ltd."Announcement on Investment in Construction of Green Bio‑manufacturing Project by Wholly‑owned Subsidiary

"Shandong Lukang Pharmaceutical Co., Ltd."Announcement on the Proposed Selection in the 12th Batch of National Centralized Drug Procurement

"Shandong Lukang Pharmaceutical Co., Ltd."Announcement on Completion of Industrial and Commercial Change Registration by a Wholly-Owned Subsidiary

"Shandong Lukang Pharmaceutical Co., Ltd."Announcement on Obtaining Drug Registration Certificate and Notice on Approval for Marketing of Chemical API

"Shandong Lukang Pharmaceutical Co., Ltd."Announcement on Implementation of Dividend Distribution for 2025

"Shandong Lukang Pharmaceutical Co., Ltd."Announcement on Change of Name and Business Scope of Wholly-owned Subsidiary

"Shandong Lukang Pharmaceutical Co., Ltd."Announcement on Acquisition of Drug Registration Certificate by a Holding Subsidiary

Announcement on Circulation of Restricted Shares Issued to Specific Objects

Announcement on Obtaining Approval for Marketing of Chemical API Aprepitant

Announcement on Obtaining Drug Registration Certificate

Announcement on Resolutions of the 2025 Annual General Meeting

Annual Report on Continuous Supervision for 2025 of Shandong Lukang Pharmaceutical Co., Ltd. by China International Capital Corporation Limited

Announcement on Resolutions of the 13th Meeting of the 11th Board of Directors

Announcement on Progress in Bid for the Equity of Shandong Luhang Hecheng Pharmaceutical Co., Ltd.

Announcement on Completion of Inclusion of the First Subject in Phase IIb Clinical Trial of CMS203 Tablets

Announcement on the Holding Subsidiary Obtaining the Supplementary Application Approval Notice for Sildenafil Citrate Tablets and Becoming the Marketing Authorization Holder of the Drug

Announcement on Acquisition of Drug Registration Certificate by a Holding Subsidiary

Announcement on Progress in Receiving Land Collection and Storage Compensation for the Southern Factory Area

Announcement on "Corporate Value and Return Enhancement" Action Plan

Earnings Preannouncement for 2025

Announcement on Using Partial Idle Raised Funds to Temporarily Supplement Current Capital

Announcement on the Results of Issuing Shares to Specific Objects and Changes in Capital Stock

Announcement on the Company and Its Wholly-Owned Subsidiary Signing the Fundraising Special Account Custody and Supervision Agreement

Indicative Announcement on the Issuance of A-shares to Specific Objects in 2024

Announcement on Signing Trademark License Agreement with Related Parties and Related Party Transactions

Announcement on Obtaining Government Subsidies

Prospectus for Issuance of A-shares to Specific Objects in 2024 (Registration Draft)

Announcement on the Company and Its Holding Subsidiaries Being Selected as Successful Bidders in the 11th Round of National Centralized Drug Procurement

Report for Q3 2025

Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025

Announcement on Obtaining Registration Approval of Application for Issuance of Shares to Specific Objects by China Securities Regulatory Commission

Announcement on Resolutions of the 9th (Extraordinary) Meeting of the 11th Board of Supervisors

Announcement on Convening the 2025 Semi-annual Performance Briefing

Announcement on the Holding Subsidiary Obtaining the Supplementary Application Approval Notice for Methocarbamol Injection and Becoming the Marketing Authorization Holder of the Drug

Announcement on Canceling the Board of Supervisors and Amending the Articles of Association, and Revising, Formulating and Abolishing Some Goverance Systems

Announcement on SSE Approval of Application for Issuance of Shares to Specific Objects

Announcement on Completion of Inclusion of the First Subject in Phase 1 Clinical Trial of CIGB-814 for Injection

Announcement on Cefuroxime Axetil for Suspension Passing Consistency Evaluation

Indicative Announcement on Reply Update to Letter of Review and Inquiry on Application Documents for Shares Issuance to Specific Objects

Semi-annual Earnings Preannouncement for 2025